SBIR/STTR Research Award
Optimizing correction of the Huntington's disease mutation by trans-splicing
Award amount
$226,921Program and phase
SBIR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- RETROTHERAPY, LLC
- Proposal award date
- 2015-09-30
- Contract end date
- 2016-09-29
- UEI
- Not reported
- Solicitation number
- PA14-071
- Topic code
- 102
Research abstract
DESCRIPTION provided by applicant Recent studies by my laboratory and collaborators and by others have demonstrated that RNA trans splicing can correct mutations in many different genes in a wide range of disease model systems including Huntingtonandapos s disease Trans splicing is one of a handful of techniques that can convert the expression of a dominant negative mutation into the normal protein thus simultaneously reducing the cause of the disease and increasing the amount of a necessary protein Trans splicing is the only method that can achieve these results without the requirement for cell division We intend to develop optimal RNA trans splicing molecules RTMs to repair the CAG triplet repeat expansion in exon of the huntingtin gene which is the cause of Huntingtonandapos s disease Huntingtin targeted RTMs will be evaluated for their ability to efficiently and specifically trans splice and replace huntigtin exon at the RNA level by RT PCR at the protein level by Western blot and for their ability to minimize cellular toxicity in differentiated Huntingtonandapos s disease patient iPSC derived striatal neurons by nuclear condensation CellTiter Glo Cell Viability assay TUNEL assay and time lapse microscopy pre clinical candidate RTMs will be identified that most efficiently correct the expression of HTT with minimal toxicity for further development
PUBLIC HEALTH RELEVANCE We intend to identify optimal therapeutic candidates to correct the causative mutation of Huntingtonandapos s disease by RNA trans splicing This could lead to the development of a treatment for patients with Huntingtonandapos s disease and ultimately for other genetic disorders
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer